{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:56:54Z","timestamp":1792454214054,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40263-025-01236-x","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:32:50Z","timestamp":1759941170000},"page":"181-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ethnicity-Based Personalized Clozapine Titration Strategies for Prevention of Clozapine-Induced Inflammation: Recommendations Based on Evidence from the Japanese Population"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1184-8918","authenticated-orcid":false,"given":"Yuki","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9354-3457","authenticated-orcid":false,"given":"Bunichiro","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-0281","authenticated-orcid":false,"given":"Hiroshi","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2628-880X","authenticated-orcid":false,"given":"Hiroaki","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"2","key":"1236_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2215-0366(24)00366-3","volume":"12","author":"H Taipale","year":"2025","unstructured":"Taipale H, Tanskanen A, Howes O, Correll CU, Kane JM, Tiihonen J. Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study. Lancet Psychiatry. 2025;12(2):122\u201330. https:\/\/doi.org\/10.1016\/S2215-0366(24)00366-3.","journal-title":"Lancet Psychiatry"},{"key":"1236_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21:248\u201371. https:\/\/doi.org\/10.1002\/wps.20994.","journal-title":"World Psychiatry"},{"key":"1236_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euroneuro.2024.04.012","volume":"84","author":"O Agid","year":"2024","unstructured":"Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Howes OD, Sepp\u00e4l\u00e4 N, et al. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice. Eur Neuropsychopharmacol. 2024;84:35\u201347. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.04.012.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1236_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1176\/appi.ps.20240110","volume":"76","author":"EF Torrey","year":"2025","unstructured":"Torrey EF, Lieberman J. The underuse of clozapine and long-acting injectable antipsychotics. Psychiatr Serv. 2025;76:90\u20132. https:\/\/doi.org\/10.1176\/appi.ps.20240110.","journal-title":"Psychiatr Serv"},{"key":"1236_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0957154X07070335","volume":"18","author":"J Crilly","year":"2007","unstructured":"Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18:39\u201360. https:\/\/doi.org\/10.1177\/0957154X07070335.","journal-title":"Hist Psychiatry"},{"key":"1236_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/JCP.0000000000001990","volume":"45","author":"J de Leon","year":"2025","unstructured":"de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, et al. Letter to the FDA proposing major changes in the US clozapine package insert supported by clozapine experts worldwide. Part II: a review of fatal outcomes in US pharmacovigilance data and proposed changes. J Clin Psychopharmacol. 2025;45:197\u2013218. https:\/\/doi.org\/10.1097\/JCP.0000000000001990.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR7","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1816","volume":"68","author":"H Verdoux","year":"2025","unstructured":"Verdoux H, Bittner RA, Hasan A, Qubad M, Wagner E, Lepetit A, et al. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force. Eur Psychiatry. 2025;68:e17. https:\/\/doi.org\/10.1192\/j.eurpsy.2024.1816.","journal-title":"Eur Psychiatry"},{"key":"1236_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.schres.2023.09.024","volume":"268","author":"PFJ Schulte","year":"2024","unstructured":"Schulte PFJ, Veerman SRT, Bakker B, Bogers JPAM, Jongkind A, Cohen D. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed? Schizophr Res. 2024;268:74\u201381. https:\/\/doi.org\/10.1016\/j.schres.2023.09.024.","journal-title":"Schizophr Res"},{"key":"1236_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.1155","author":"DL Kelly","year":"2025","unstructured":"Kelly DL, Kane JM, Love RC, Cotes RO. FDA eliminates the clozapine REMS-what comes next? JAMA Psychiatr. 2025. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1155.","journal-title":"JAMA Psychiatr"},{"key":"1236_CR10","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.89","author":"E Wagner","year":"2025","unstructured":"Wagner E, Korman N, Solmi M, Mortazavi M, Aminifarsani Z, Dubrovin Le\u00e3o D, et al. Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis. Br J Psychiatry. 2025. https:\/\/doi.org\/10.1192\/bjp.2025.89.","journal-title":"Br J Psychiatry"},{"key":"1236_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JCP.0000000000001987","volume":"45","author":"J de Leon","year":"2025","unstructured":"de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, et al. Letter to the FDA proposing major changes in the US clozapine package insert supported by clozapine experts worldwide. Part I: a review of the pharmacokinetic literature and proposed changes. J Clin Psychopharmacol. 2025;45:179\u201396. https:\/\/doi.org\/10.1097\/JCP.0000000000001987.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1625-6388","volume":"55","author":"J de Leon","year":"2022","unstructured":"de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Sepp\u00e4l\u00e4 N, et al. An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry. 2022;55:73\u201386. https:\/\/doi.org\/10.1055\/a-1625-6388.","journal-title":"Pharmacopsychiatry"},{"key":"1236_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae213","author":"Y Kikuchi","year":"2024","unstructured":"Kikuchi Y, Otsuka Y, Ito F, Yada Y, Tanifuji H, Komatsu H, et al. Relationship between clozapine-induced inflammation and eosinophilia: a retrospective cohort study. Schizophr Bull. 2024. https:\/\/doi.org\/10.1093\/schbul\/sbae213.","journal-title":"Schizophr Bull"},{"key":"1236_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.schres.2023.06.003","volume":"268","author":"Y Kikuchi","year":"2024","unstructured":"Kikuchi Y, Komatsu H, Otsuka Y, Ito F, Kanahara N, Tanifuji H, et al. Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: a retrospective chart review of seven hospitals. Schizophr Res. 2024;268:98\u2013106. https:\/\/doi.org\/10.1016\/j.schres.2023.06.003.","journal-title":"Schizophr Res"},{"key":"1236_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-023-00412-6","volume":"9","author":"Y Kikuchi","year":"2023","unstructured":"Kikuchi Y, Yada Y, Otsuka Y, Ito F, Tanifuji H, Komatsu H, et al. Slower clozapine titration is associated with delayed onset of clozapine-induced fever among Japanese patients with schizophrenia. Schizophrenia (Heidelberg). 2023;9:82. https:\/\/doi.org\/10.1038\/s41537-023-00412-6.","journal-title":"Schizophrenia (Heidelberg)"},{"key":"1236_CR16","doi-asserted-by":"publisher","first-page":"1366621","DOI":"10.3389\/fpsyt.2024.1366621","volume":"15","author":"Y Kikuchi","year":"2024","unstructured":"Kikuchi Y, Tanifuji H, Ueno S, Onuma Y, Goto M, Ishihara M, et al. Patterns of C-reactive protein trends during clozapine titration and the onset of clozapine-induced inflammation: a case series of weekly and daily C-reactive protein monitoring. Front Psychiatry. 2024;15:1366621. https:\/\/doi.org\/10.3389\/fpsyt.2024.1366621.","journal-title":"Front Psychiatry"},{"key":"1236_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1192\/bjp.2024.113","volume":"225","author":"Y Kikuchi","year":"2024","unstructured":"Kikuchi Y, Kurosawa M, Sakata M, Takahashi Y, Yamamoto K, Tomita H, et al. Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals. Br J Psychiatry. 2024;225:492\u20138. https:\/\/doi.org\/10.1192\/bjp.2024.113.","journal-title":"Br J Psychiatry"},{"key":"1236_CR18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/phar.2887","volume":"43","author":"JG Leung","year":"2023","unstructured":"Leung JG, Zhang L, Markota M, Ellingrod VL, Gerberi DJ, Bishop JR. A systematic review of clozapine-associated inflammation and related monitoring. Pharmacotherapy. 2023;43:1364\u201396. https:\/\/doi.org\/10.1002\/phar.2887.","journal-title":"Pharmacotherapy"},{"key":"1236_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2019.07.040","volume":"211","author":"H Verdoux","year":"2019","unstructured":"Verdoux H, Quiles C, de Leon J. Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review. Schizophr Res. 2019;211:1\u20139. https:\/\/doi.org\/10.1016\/j.schres.2019.07.040.","journal-title":"Schizophr Res"},{"key":"1236_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/schbul\/sbz093","volume":"46","author":"J De Leon","year":"2020","unstructured":"De Leon J, Sanz EJ, De Las Cuevas C. Data from the World Health Organization\u2019s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull. 2020;46:1\u20133. https:\/\/doi.org\/10.1093\/schbul\/sbz093.","journal-title":"Schizophr Bull"},{"key":"1236_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1176\/appi.ajp.20230744","volume":"181","author":"JJ Partanen","year":"2024","unstructured":"Partanen JJ, H\u00e4pp\u00f6l\u00e4 P, K\u00e4mpe A, Ahola-Olli A, Hellsten A, Rask SM, et al. High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-year follow-up register study. Am J Psychiatry. 2024;181:879\u201392. https:\/\/doi.org\/10.1176\/appi.ajp.20230744.","journal-title":"Am J Psychiatry"},{"key":"1236_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60122016","volume":"60","author":"V Zhao","year":"2024","unstructured":"Zhao V, Gong Y, Thomas N, Das S. Clozapine and pneumonia: synthesizing the link by reviewing existing reports\u2014a systematic review and meta-analysis. Medicina (Kaunas). 2024;60:2016. https:\/\/doi.org\/10.3390\/medicina60122016.","journal-title":"Medicina (Kaunas)"},{"key":"1236_CR23","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1177\/02698811211021587","volume":"35","author":"R de Filippis","year":"2021","unstructured":"de Filippis R, Soldevila-Mat\u00edas P, Guinart D, De Fazio P, Rubio JM, Kane JM, et al. Unravelling cases of clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) in patients reported otherwise: a systematic review. J Psychopharmacol. 2021;35:1062\u201373. https:\/\/doi.org\/10.1177\/02698811211021587.","journal-title":"J Psychopharmacol"},{"key":"1236_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ajp.2017.04.013","volume":"28","author":"H Hassine","year":"2017","unstructured":"Hassine H, Ouali U, Ouertani A, Jomli R, Nacef F. Clozapine-induced DRESS syndrome with multiple and rare organ involvement. Asian J Psychiatr. 2017;28:146\u20137. https:\/\/doi.org\/10.1016\/j.ajp.2017.04.013.","journal-title":"Asian J Psychiatr"},{"key":"1236_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12888-016-1158-1","volume":"16","author":"E Bugge","year":"2016","unstructured":"Bugge E, Nissen T, Wynn R. Probable clozapine-induced parenchymal lung disease and perimyocarditis: a case report. BMC Psychiatry. 2016;16:438. https:\/\/doi.org\/10.1186\/s12888-016-1158-1.","journal-title":"BMC Psychiatry"},{"key":"1236_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/ndtplus\/sfm003","volume":"1","author":"BK Siddiqui","year":"2008","unstructured":"Siddiqui BK, Asim S, Shamim A, Pillai N, Rajan S. Simultaneous allergic interstitial nephritis and cardiomyopathy in a patient on clozapine. NDT Plus. 2008;1:55\u20136. https:\/\/doi.org\/10.1093\/ndtplus\/sfm003.","journal-title":"NDT Plus"},{"key":"1236_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/JCP.0000000000000900","volume":"38","author":"G Dimitri Valente","year":"2018","unstructured":"Dimitri Valente G, Dusi N, Lasalvia A. An idiosyncratic, acute, systemic, and life-threatening adverse reaction in a young patient treated with clozapine: a case report. J Clin Psychopharmacol. 2018;38:387\u20139. https:\/\/doi.org\/10.1097\/JCP.0000000000000900.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/JCP.0000000000001365","volume":"41","author":"MI Yildiz","year":"2021","unstructured":"Yildiz MI, Karacam Dogan M, Mutlu E, Abdullayeva L, Ozmen F, Ertugrul A. All in one: clozapine-associated acute pancreatitis with multiple organ involvement. J Clin Psychopharmacol. 2021;41:214\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000001365.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.24869\/psyd.2022.411","volume":"34","author":"J de Leon","year":"2022","unstructured":"de Leon J. Reflections on the complex history of the concept of clozapine-induced inflammation during titration. Psychiatr Danub. 2022;34:411\u201321. https:\/\/doi.org\/10.24869\/psyd.2022.411.","journal-title":"Psychiatr Danub"},{"key":"1236_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40263-024-01100-4","volume":"38","author":"M Qubad","year":"2024","unstructured":"Qubad M, Dupont G, Hahn M, Martin SS, Puntmann V, Nagel E, et al. When, why and how to re-challenge clozapine in schizophrenia following myocarditis. CNS Drugs. 2024;38:671\u201396. https:\/\/doi.org\/10.1007\/s40263-024-01100-4.","journal-title":"CNS Drugs"},{"key":"1236_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.38","volume":"1","author":"Y Kikuchi","year":"2022","unstructured":"Kikuchi Y, Komatsu H, Sakuma A, Tanifuji H, Tomita H. Successful rechallenge with clozapine after discontinuation due to drug-induced pneumonia: a case report. PCN Rep. 2022;1:e38. https:\/\/doi.org\/10.1002\/pcn5.38.","journal-title":"PCN Rep"},{"key":"1236_CR32","first-page":"153","volume":"24","author":"C Shelton","year":"2022","unstructured":"Shelton C, Ruan CJ, Ertu\u011frul A, Cotes RO, De Leon J. Should we routinely add CRP to clozapine titrations? Learning from three cases. Neuropsychopharmacol Hung. 2022;24:153\u201361.","journal-title":"Neuropsychopharmacol Hung"},{"key":"1236_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00004714-199706000-00022","volume":"17","author":"A Chatterjee","year":"1997","unstructured":"Chatterjee A, Safferman AZ. Cellulitis, eosinophilia, and unilateral pleural effusion associated with clozapine treatment. J Clin Psychopharmacol. 1997;17:232\u20133. https:\/\/doi.org\/10.1097\/00004714-199706000-00022.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1055\/a-0586-8983","volume":"52","author":"B Sanader","year":"2019","unstructured":"Sanader B, Grohmann R, Gr\u00f6tsch P, Schumann T, Toto S, Fernando P, et al. Clozapine-induced DRESS syndrome: a case series from the AMSP multicenter drug safety surveillance project. Pharmacopsychiatry. 2019;52:156\u20139. https:\/\/doi.org\/10.1055\/a-0586-8983.","journal-title":"Pharmacopsychiatry"},{"key":"1236_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-025-00648-4","volume":"11","author":"B Onodera","year":"2025","unstructured":"Onodera B, Sakata M, Ikawa K, Kume D, Horikawa N, Komatsu H, et al. Elevated neutrophil-to-lymphocyte ratios correlate with increased clozapine concentration-to-dose ratios during titration. Schizophrenia (Heidelberg). 2025;11:96. https:\/\/doi.org\/10.1038\/s41537-025-00648-4.","journal-title":"Schizophrenia (Heidelberg)"},{"key":"1236_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/00048674.2011.572852","volume":"45","author":"KJ Ronaldson","year":"2011","unstructured":"Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45:458\u201365. https:\/\/doi.org\/10.3109\/00048674.2011.572852.","journal-title":"Aust N Z J Psychiatry"},{"key":"1236_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/jgf2.239","volume":"20","author":"Y Otsuka","year":"2019","unstructured":"Otsuka Y, Idemoto K, Hosoda Y, Imamura Y, Aoki T. Clozapine-induced myocarditis: follow-up for 3.5 years after successful retrial. J Gen Fam Med. 2019;20:114\u20137. https:\/\/doi.org\/10.1002\/jgf2.239.","journal-title":"J Gen Fam Med"},{"key":"1236_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2024.111104","volume":"218","author":"L Shao","year":"2024","unstructured":"Shao L, Li Y, Yuan Z, Guo X, Zeng G, Liu J. The effect of clozapine on immune-related biomarkers in schizophrenia patients. Brain Res Bull. 2024;218:111104. https:\/\/doi.org\/10.1016\/j.brainresbull.2024.111104.","journal-title":"Brain Res Bull"},{"issue":"Suppl 1","key":"1236_CR39","doi-asserted-by":"publisher","first-page":"i165","DOI":"10.1093\/ijnp\/pyae059.286","volume":"28","author":"J Noh","year":"2025","unstructured":"Noh J, Ryu H. A case report of clozapine-induced myocarditis in a 27-yea\u2014old schizophrenia patient. Int J Neuropsychopharmacol. 2025;28(Suppl 1):i165\u20136. https:\/\/doi.org\/10.1093\/ijnp\/pyae059.286.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1236_CR40","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1016\/S0735-1097(23)04225-0","volume":"81","author":"M Shnoda","year":"2023","unstructured":"Shnoda M, Sagalov A, Patel H, Siddique M, Hegde S. Clozapine-induced myocarditis: a rare case of myocarditis with life-threatening implications. J Am Coll Cardiol. 2023;81:3781. https:\/\/doi.org\/10.1016\/S0735-1097(23)04225-0.","journal-title":"J Am Coll Cardiol"},{"key":"1236_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4088\/JCP.v59n0409c","volume":"59","author":"MJ Lucht","year":"1998","unstructured":"Lucht MJ, Rietschel M. Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms. J Clin Psychiatry. 1998;59:195\u20137. https:\/\/doi.org\/10.4088\/JCP.v59n0409c.","journal-title":"J Clin Psychiatry"},{"key":"1236_CR42","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.4088\/jcp.v68n0726d","volume":"68","author":"K K\u00f6rtner","year":"2007","unstructured":"K\u00f6rtner K, Neuhaus AH, Sch\u00fcrer F, Dettling M. Eosinophilia indicating subclinical clozapine-induced pericarditis. J Clin Psychiatry. 2007;68:1147\u20138. https:\/\/doi.org\/10.4088\/jcp.v68n0726d.","journal-title":"J Clin Psychiatry"},{"key":"1236_CR43","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S0022-3565(25)24566-9","volume":"272","author":"M Pirmohamed","year":"1995","unstructured":"Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995;272:984\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"1236_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/FTD.0000000000001177","volume":"46","author":"BM Wollmann","year":"2024","unstructured":"Wollmann BM, Haugen AG, Smith RL, Molden E. Novel identification of cysteinyl derivatives of toxic clozapine nitrenium ions and the effect of valproic acid on metabolite formation: a study using reprocessed high-resolution mass spectra of analyzed therapeutic drug monitoring samples. Ther Drug Monit. 2024;46:265\u20139. https:\/\/doi.org\/10.1097\/FTD.0000000000001177.","journal-title":"Ther Drug Monit"},{"key":"1236_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12012-014-9304-9","volume":"15","author":"BA Abdel-Wahab","year":"2015","unstructured":"Abdel-Wahab BA, Metwally ME. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-\u03ba\u03b2. Cardiovasc Toxicol. 2015;15:355\u201365. https:\/\/doi.org\/10.1007\/s12012-014-9304-9.","journal-title":"Cardiovasc Toxicol"},{"key":"1236_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejphar.2008.06.088","volume":"592","author":"JF Wang","year":"2008","unstructured":"Wang JF, Min JY, Hampton TG, Amende I, Yan X, Malek S, et al. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur J Pharmacol. 2008;592:123\u20137. https:\/\/doi.org\/10.1016\/j.ejphar.2008.06.088.","journal-title":"Eur J Pharmacol"},{"key":"1236_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.schres.2012.08.018","volume":"141","author":"KJ Ronaldson","year":"2012","unstructured":"Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res. 2012;141:173\u20138. https:\/\/doi.org\/10.1016\/j.schres.2012.08.018.","journal-title":"Schizophr Res"},{"key":"1236_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/acps.12416","volume":"132","author":"KJ Ronaldson","year":"2015","unstructured":"Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand. 2015;132:231\u201340. https:\/\/doi.org\/10.1111\/acps.12416.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.euroneuro.2022.04.009","volume":"60","author":"R de Filippis","year":"2022","unstructured":"de Filippis R, Kane JM, Kuzo N, Spina E, De Sarro G, de Leon J, et al. Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. Eur Neuropsychopharmacol. 2022;60:25\u201337. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.04.009.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1236_CR50","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/070674370805301211","volume":"53","author":"J Pui-yin Chung","year":"2008","unstructured":"Pui-yin Chung J, Shiu-yin Chong C, Chung KF, Lai-wah Dunn E, Wai-nang Tang O, Chan WF. The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry. 2008;53:857\u201362. https:\/\/doi.org\/10.1177\/070674370805301211.","journal-title":"Can J Psychiatry"},{"key":"1236_CR51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/bcp.15691","volume":"90","author":"S Reeves","year":"2024","unstructured":"Reeves S, Bertrand J, Obee SJ, Hunter S, Howard R, Flanagan RJ. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol. 2024;90:135\u201345. https:\/\/doi.org\/10.1111\/bcp.15691.","journal-title":"Br J Clin Pharmacol"},{"key":"1236_CR52","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22ac14500","volume":"83","author":"G Schoretsanitis","year":"2022","unstructured":"Schoretsanitis G, de Leon J. Best practices for starting clozapine in patients with schizophrenia: how to switch from the prior antipsychotic(s). J Clin Psychiatry. 2022;83:22ac14500. https:\/\/doi.org\/10.4088\/JCP.22ac14500.","journal-title":"J Clin Psychiatry"},{"key":"1236_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114247","volume":"305","author":"N Richardson","year":"2021","unstructured":"Richardson N, Greenway SC, Bousman CA. Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: a systematic case review. Psychiatry Res. 2021;305:114247.","journal-title":"Psychiatry Res"},{"key":"1236_CR54","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/acps.13228","volume":"142","author":"E Wagner","year":"2020","unstructured":"Wagner E, McMahon L, Falkai P, Hasan A, Siskind D. Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis. Acta Psychiatr Scand. 2020;142:456\u201366. https:\/\/doi.org\/10.1111\/acps.13228.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","volume":"36","author":"S Zevin","year":"1999","unstructured":"Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36:425\u201338. https:\/\/doi.org\/10.2165\/00003088-199936060-00004.","journal-title":"Clin Pharmacokinet"},{"key":"1236_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/acps.13801","volume":"152","author":"RL Smith","year":"2025","unstructured":"Smith RL, Andreassen OA, Kane JM, Schoretsanitis G, Molden E. Correlation between clozapine and CRP levels in relation to smoking status. Acta Psychiatr Scand. 2025;152:69\u201376. https:\/\/doi.org\/10.1111\/acps.13801.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR57","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","volume":"192","author":"SR Clark","year":"2018","unstructured":"Clark SR, Warren NS, Kim G, Jankowiak D, Schubert KO, Kisely S, et al. Elevated clozapine levels associated with infection: a systematic review. Schizophr Res. 2018;192:50\u20136. https:\/\/doi.org\/10.1016\/j.schres.2017.03.045.","journal-title":"Schizophr Res"},{"key":"1236_CR58","first-page":"29","volume":"24","author":"M Koenig","year":"2022","unstructured":"Koenig M, McCollum B, Spivey JK, Coleman JK, Shelton C, Cotes RO, et al. Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases. Neuropsychopharmacol Hung. 2022;24:29\u201341.","journal-title":"Neuropsychopharmacol Hung"},{"key":"1236_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/acps.13810","volume":"152","author":"Y Kikuchi","year":"2025","unstructured":"Kikuchi Y. The higher dose-adjusted clozapine concentrations in nonsmokers with high CRP levels may be associated with the lower daily doses of clozapine. Acta Psychiatr Scand. 2025;152:148\u20139. https:\/\/doi.org\/10.1111\/acps.13810.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR60","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/acps.13398","volume":"145","author":"M Vickers","year":"2022","unstructured":"Vickers M, Ramineni V, Malacova E, Eriksson L, McMahon K, Moudgil V, et al. Risk factors for clozapine-induced myocarditis and cardiomyopathy: a systematic review and meta-analysis. Acta Psychiatr Scand. 2022;145:442\u201355. https:\/\/doi.org\/10.1111\/acps.13398.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115810","volume":"334","author":"Y Kikuchi","year":"2024","unstructured":"Kikuchi Y, Komatsu H, Otsuka Y, Ito F, Yada Y, Tanifuji H, et al. Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia. Psychiatry Res. 2024;334:115810. https:\/\/doi.org\/10.1016\/j.psychres.2024.115810.","journal-title":"Psychiatry Res"},{"key":"1236_CR62","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/FTD.0000000000000705","volume":"42","author":"J de Leon","year":"2020","unstructured":"de Leon J. Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and\/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid. Ther Drug Monit. 2020;42:159\u201361. https:\/\/doi.org\/10.1097\/FTD.0000000000000705.","journal-title":"Ther Drug Monit"},{"key":"1236_CR63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17512433.2022.2032659","volume":"15","author":"C De Las Cuevas","year":"2022","unstructured":"De Las Cuevas C, Sanz EJ, Rohde C, de Leon J. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase. Expert Rev Clin Pharmacol. 2022;15:65\u201378. https:\/\/doi.org\/10.1080\/17512433.2022.2032659.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1236_CR64","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.schres.2023.08.001","volume":"268","author":"N Kang","year":"2024","unstructured":"Kang N, Kim SH, Kim J, Kim S, Jang J, Yoon H, et al. Association between initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital. Schizophr Res. 2024;268:131\u20137. https:\/\/doi.org\/10.1016\/j.schres.2023.08.001.","journal-title":"Schizophr Res"},{"key":"1236_CR65","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1176\/ajp.147.11.1471","volume":"147","author":"C Haring","year":"1990","unstructured":"Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry. 1990;147:1471\u20135. https:\/\/doi.org\/10.1176\/ajp.147.11.1471.","journal-title":"Am J Psychiatry"},{"key":"1236_CR66","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s00394-020-02421-y","volume":"60","author":"M Zarezadeh","year":"2021","unstructured":"Zarezadeh M, Saedisomeolia A, Shekarabi M, Khorshidi M, Emami MR, M\u00fcller DJ. The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. Eur J Nutr. 2021;60:2905\u201321. https:\/\/doi.org\/10.1007\/s00394-020-02421-y.","journal-title":"Eur J Nutr"},{"key":"1236_CR67","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0269881120985166","volume":"35","author":"M Kuzin","year":"2021","unstructured":"Kuzin M, Haen E, Hiemke C, Bochon B, Bochon K, Gr\u00fcnder G, et al. Body mass index as a determinant of clozapine plasma concentrations: a pharmacokinetic-based hypothesis. J Psychopharmacol. 2021;35:273\u20138. https:\/\/doi.org\/10.1177\/0269881120985166.","journal-title":"J Psychopharmacol"},{"key":"1236_CR68","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/JCP.0000000000000926","volume":"38","author":"FJ Diaz","year":"2018","unstructured":"Diaz FJ, Josiassen RC, de Leon J. The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial. J Clin Psychopharmacol. 2018;38:442\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000000926.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR69","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s42255-024-01079-8","volume":"6","author":"O Le Thuc","year":"2024","unstructured":"Le Thuc O, Garc\u00eda-C\u00e1ceres C. Obesity-induced inflammation: connecting the periphery to the brain. Nat Metab. 2024;6:1237\u201352. https:\/\/doi.org\/10.1038\/s42255-024-01079-8.","journal-title":"Nat Metab"},{"key":"1236_CR70","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1124\/jpet.107.124024","volume":"322","author":"WV Zhang","year":"2007","unstructured":"Zhang WV, Ramzan I, Murray M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J Pharmacol Exp Ther. 2007;322:770\u20137. https:\/\/doi.org\/10.1124\/jpet.107.124024.","journal-title":"J Pharmacol Exp Ther"},{"key":"1236_CR71","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.schres.2024.01.030","volume":"264","author":"S Tirupati","year":"2024","unstructured":"Tirupati S, Arachchi MK. High rates of myocarditis with clozapine in the Hunter region of Australia. Schizophr Res. 2024;264:543\u20138. https:\/\/doi.org\/10.1016\/j.schres.2024.01.030.","journal-title":"Schizophr Res"},{"key":"1236_CR72","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.schres.2024.03.004","volume":"267","author":"Y Kikuchi","year":"2024","unstructured":"Kikuchi Y, Komatsu H, Tomita H. Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter region of Australia. Schizophr Res. 2024;267:42\u20133. https:\/\/doi.org\/10.1016\/j.schres.2024.03.004.","journal-title":"Schizophr Res"},{"key":"1236_CR73","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.schres.2024.03.005","volume":"267","author":"S Tirupati","year":"2024","unstructured":"Tirupati S, Arachchi MK. Reply to \u201cObesity as a potential confounder of clozapine-induced myocarditis in the Hunter Region of Australia.\u201d Schizophr Res. 2024;267:191\u20132. https:\/\/doi.org\/10.1016\/j.schres.2024.03.005.","journal-title":"Schizophr Res"},{"key":"1236_CR74","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/JGP.0b013e3182118318","volume":"20","author":"Z Ismail","year":"2012","unstructured":"Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK, et al. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 2012;20:53\u201360. https:\/\/doi.org\/10.1097\/JGP.0b013e3182118318.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1236_CR75","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/acps.12794","volume":"136","author":"I Castberg","year":"2017","unstructured":"Castberg I, Westin AA, Skogvoll E, Spigset O. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 2017;136:455\u201364. https:\/\/doi.org\/10.1111\/acps.12794.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR76","doi-asserted-by":"publisher","first-page":"1356813","DOI":"10.3389\/fphar.2024.1356813","volume":"15","author":"A Mach","year":"2024","unstructured":"Mach A, Wnorowska A, Siwek M, Wojnar M, Radziwo\u0144-Zaleska M. Clinical and pharmacological factors influencing serum clozapine and norclozapine levels. Front Pharmacol. 2024;15:1356813. https:\/\/doi.org\/10.3389\/fphar.2024.1356813.","journal-title":"Front Pharmacol"},{"key":"1236_CR77","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S2215-0366(23)00002-0","volume":"10","author":"AF Pardi\u00f1as","year":"2023","unstructured":"Pardi\u00f1as AF, Kappel DB, Roberts M, Tipple F, Shitomi-Jones LM, King A, et al. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. Lancet Psychiatry. 2023;10:209\u201319. https:\/\/doi.org\/10.1016\/S2215-0366(23)00002-0.","journal-title":"Lancet Psychiatry"},{"key":"1236_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.70","volume":"2","author":"N Yasui-Furukori","year":"2023","unstructured":"Yasui-Furukori N, Otsuka Y, de Leon J. Japanese patients need slower, personalized clozapine titrations: a comment on the case described by Kikuchi et al. PCN Rep. 2023;2:e70. https:\/\/doi.org\/10.1002\/pcn5.70.","journal-title":"PCN Rep"},{"key":"1236_CR79","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/JCP.0000000000001843","volume":"44","author":"J de Leon","year":"2024","unstructured":"de Leon J. Can slow personalized titration using C-reactive protein monitoring decrease the high rates and mortality of clozapine-associated myocarditis seen in some countries? A call for research. J Clin Psychopharmacol. 2024;44:212\u20139. https:\/\/doi.org\/10.1097\/JCP.0000000000001843.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR80","unstructured":"The Expert Committee for Clozaril Patient Monitoring Service. https:\/\/www.clozaril-tekisei.jp\/registered-medical-institutions. Accessed 15 Aug 2025."},{"key":"1236_CR81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/acps.12742","volume":"136","author":"CJ Bachmann","year":"2017","unstructured":"Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136:37\u201351. https:\/\/doi.org\/10.1111\/acps.12742.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR82","doi-asserted-by":"publisher","DOI":"10.1017\/S204579602200066X","volume":"31","author":"E Oloyede","year":"2022","unstructured":"Oloyede E, Blackman G, Whiskey E, Bachmann C, Dzahini O, Shergill S, et al. Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiol Psychiatr Sci. 2022;31:e83. https:\/\/doi.org\/10.1017\/S204579602200066X.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"1236_CR83","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.schres.2023.10.011","volume":"268","author":"T Niitsu","year":"2024","unstructured":"Niitsu T, Yasui-Furukori N, Inada K, Kanazawa T, Iyo M, Ueno T, et al. Current practice for clozapine-induced leukopenia in Japanese psychiatric hospitals: a nationwide survey. Schizophr Res. 2024;268:82\u20137. https:\/\/doi.org\/10.1016\/j.schres.2023.10.011.","journal-title":"Schizophr Res"},{"key":"1236_CR84","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ijnp\/pyac036","volume":"25","author":"S Ochi","year":"2022","unstructured":"Ochi S, Tagata H, Hasegawa N, Yasui-Furukori N, Iga JI, Kashiwagi H, et al. Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: a real-world nationwide study. Int J Neuropsychopharmacol. 2022;25:818\u201326. https:\/\/doi.org\/10.1093\/ijnp\/pyac036.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1236_CR85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/acps.12241","volume":"130","author":"P Ifteni","year":"2014","unstructured":"Ifteni P, Nielsen J, Burtea V, Correll CU, Kane JM, Manu P. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand. 2014;130:25\u20139. https:\/\/doi.org\/10.1111\/acps.12241.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR86","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jad.2014.04.020","volume":"166","author":"P Ifteni","year":"2014","unstructured":"Ifteni P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord. 2014;166:168\u201372. https:\/\/doi.org\/10.1016\/j.jad.2014.04.020.","journal-title":"J Affect Disord"},{"key":"1236_CR87","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11126-015-9394-y","volume":"87","author":"CA Poyraz","year":"2016","unstructured":"Poyraz CA, \u00d6zdemir A, Sa\u011flam NG, Turan \u015e, Poyraz B\u00c7, Tomruk N, et al. Rapid clozapine titration in patients with treatment refractory schizophrenia. Psychiatr Q. 2016;87:315\u201322. https:\/\/doi.org\/10.1007\/s11126-015-9394-y.","journal-title":"Psychiatr Q"},{"key":"1236_CR88","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ajp.2012.10.007","volume":"6","author":"T Kishi","year":"2013","unstructured":"Kishi T, Fujita K, Furukawa O, Suzuki T, Moriwaki M, Nitta M, et al. Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: results from a 12-week, flexible dose study using raters masked to antipsychotic choice. Asian J Psychiatr. 2013;6:200\u20137. https:\/\/doi.org\/10.1016\/j.ajp.2012.10.007.","journal-title":"Asian J Psychiatr"},{"key":"1236_CR89","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11126-020-09841-3","volume":"92","author":"M Tsukahara","year":"2021","unstructured":"Tsukahara M, So R, Yada Y, Kodama M, Kishi Y. Clinical utility and safety of slower-than-recommended titration of clozapine for treatment-resistant schizophrenia: a retrospective cohort study. Psychiatr Q. 2021;92:703\u201313. https:\/\/doi.org\/10.1007\/s11126-020-09841-3.","journal-title":"Psychiatr Q"},{"key":"1236_CR90","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2023.09.029","volume":"268","author":"N Kang","year":"2024","unstructured":"Kang N, Kim SH, Kim J, Kim S, Jang J, Yoon H, et al. Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital. Schizophr Res. 2024;268:107\u201313. https:\/\/doi.org\/10.1016\/j.schres.2023.09.029.","journal-title":"Schizophr Res"},{"key":"1236_CR91","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/17425255.2024.2373111","volume":"20","author":"J de Leon","year":"2024","unstructured":"de Leon J, Ruan CJ, Schoretsanitis G, Villasante-Tezanos AG, Spina E, Sanz EJ, et al. Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia. Expert Opin Drug Metab Toxicol. 2024;20:857\u201371. https:\/\/doi.org\/10.1080\/17425255.2024.2373111.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1236_CR92","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/acps.13264","volume":"143","author":"Y Yada","year":"2021","unstructured":"Yada Y, Kitagawa K, Sakamoto S, Ozawa A, Nakada A, Kashiwagi H, et al. The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study. Acta Psychiatr Scand. 2021;143:227\u201337. https:\/\/doi.org\/10.1111\/acps.13264.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR93","doi-asserted-by":"publisher","first-page":"1591568","DOI":"10.3389\/fpsyt.2025.1591568","volume":"16","author":"Y Kikuchi","year":"2025","unstructured":"Kikuchi Y, Tanifuji H, Sakata M, Ikawa K, Kume D, Horikawa N, et al. Higher clozapine concentration-to-dose ratios at week 1 after initiation are associated with increased risk of clozapine-associated fever in Japanese patients with schizophrenia. Front Psychiatry. 2025;16:1591568. https:\/\/doi.org\/10.3389\/fpsyt.2025.1591568.","journal-title":"Front Psychiatry"},{"key":"1236_CR94","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/JCP.0000000000002003","volume":"45","author":"Y Kikuchi","year":"2025","unstructured":"Kikuchi Y, Sakata M, Ikawa K, Kume D, Horikawa N, Komatsu H, et al. Weekly changes in the clozapine concentration-to-dose ratio during clozapine titration in Japanese patients with schizophrenia. J Clin Psychopharmacol. 2025;45:345\u20138. https:\/\/doi.org\/10.1097\/JCP.0000000000002003.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/IJPSYM.IJPSYM_379_19","volume":"42","author":"J de Leon","year":"2020","unstructured":"de Leon J, Rajkumar AP, Kaithi AR, Schoretsanitis G, Kane JM, Wang CY, et al. Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview. Indian J Psychol Med. 2020;42:4\u201310. https:\/\/doi.org\/10.4103\/IJPSYM.IJPSYM_379_19.","journal-title":"Indian J Psychol Med"},{"key":"1236_CR96","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.200061","volume":"45","author":"D Siskind","year":"2020","unstructured":"Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020;45:200061. https:\/\/doi.org\/10.1503\/jpn.200061.","journal-title":"J Psychiatry Neurosci"},{"key":"1236_CR97","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/JCP.0000000000002033","volume":"45","author":"E Mutlu","year":"2025","unstructured":"Mutlu E, \u00d6z\u00e7elik Ero\u011flu E, Yildiz M\u0130, Ko\u00e7yi\u011fit D, Ertu\u011frul A, Anil Ya\u011fcio\u011flu AE. Developing a clozapine titration monitoring algorithm: integration of evidence and clinical experience at a University Hospital. J Clin Psychopharmacol. 2025;45:388\u201390. https:\/\/doi.org\/10.1097\/JCP.0000000000002033.","journal-title":"J Clin Psychopharmacol"},{"key":"1236_CR98","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2215-0366(25)00031-8","volume":"12","author":"RA McCutcheon","year":"2025","unstructured":"McCutcheon RA, Pillinger T, Varvari I, Halstead S, Ayinde OO, Crossley NA, et al. Integrate: international guidelines for the algorithmic treatment of schizophrenia. Lancet Psychiatry. 2025;12:384\u201394. https:\/\/doi.org\/10.1016\/S2215-0366(25)00031-8.","journal-title":"Lancet Psychiatry"},{"key":"1236_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085956","volume":"15","author":"MI Jakobsen","year":"2025","unstructured":"Jakobsen MI, Schaug JP, Storeb\u00f8 OJ, Austin SF, Nielsen J, Simonsen E. What is the current scope of research assessing patients\u2019 and clinicians\u2019 perspectives on clozapine treatment? A comprehensive scoping review. BMJ Open. 2025;15:e085956. https:\/\/doi.org\/10.1136\/bmjopen-2024-085956.","journal-title":"BMJ Open"},{"key":"1236_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-093394","volume":"15","author":"MI Jakobsen","year":"2025","unstructured":"Jakobsen MI, Austin SF, Storeb\u00f8 OJ, Simonsen E, Nielsen J. Perspectives of clozapine-na\u00efve outpatients with treatment-resistant schizophrenia on clozapine commencement: a mixed-methods convergent study. BMJ Open. 2025;15:e093394. https:\/\/doi.org\/10.1136\/bmjopen-2024-093394.","journal-title":"BMJ Open"},{"key":"1236_CR101","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.schres.2025.01.026","volume":"276","author":"L Matheson","year":"2025","unstructured":"Matheson L, White RF, Liu SSF, Rabkin SW, Bousman CA, Rafizadeh R. Clozapine discontinuation and rechallenge in suspected myocarditis: an analysis of seven cases. Schizophr Res. 2025;276:202\u20134. https:\/\/doi.org\/10.1016\/j.schres.2025.01.026.","journal-title":"Schizophr Res"},{"key":"1236_CR102","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/acps.12327","volume":"130","author":"K Beck","year":"2014","unstructured":"Beck K, McCutcheon R, Bloomfield MA, Gaughran F, Reis Marques T, MacCabe J, et al. The practical management of refractory schizophrenia\u2014the Maudsley treatment review and assessment team service approach. Acta Psychiatr Scand. 2014;130:427\u201338. https:\/\/doi.org\/10.1111\/acps.12327.","journal-title":"Acta Psychiatr Scand"},{"key":"1236_CR103","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1176\/ps.49.8.1034","volume":"49","author":"DJ Luchins","year":"1998","unstructured":"Luchins DJ, Hanrahan P, Shinderman M, Lagios L, Fichtner CG. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. Psychiatr Serv. 1998;49:1034\u20138. https:\/\/doi.org\/10.1176\/ps.49.8.1034.","journal-title":"Psychiatr Serv"},{"key":"1236_CR104","doi-asserted-by":"publisher","DOI":"10.1177\/10398562251358132","author":"J Paul","year":"2025","unstructured":"Paul J, Ayeni B, Ienco R, Waters F, Varghese S, Nguyen T, et al. Initiating clozapine in the outpatient setting: a retrospective study examining the cost-effectiveness, feasibility and safety. Australas Psychiatry. 2025. https:\/\/doi.org\/10.1177\/10398562251358132.","journal-title":"Australas Psychiatry"},{"key":"1236_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2025.104622","volume":"110","author":"J de Leon","year":"2025","unstructured":"de Leon J, Tandon R. The clozapine package inserts need to reflect lower doses for Asians. Asian J Psychiatr. 2025;110:104622. https:\/\/doi.org\/10.1016\/j.ajp.2025.104622.","journal-title":"Asian J Psychiatr"},{"key":"1236_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2025.104626","volume":"110","author":"C De Las Cuevas","year":"2025","unstructured":"De Las Cuevas C. On dosing equity, scientific responsibility, and what remains unsaid. Asian J Psychiatr. 2025;110:104626. https:\/\/doi.org\/10.1016\/j.ajp.2025.104626.","journal-title":"Asian J Psychiatr"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01236-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:59:22Z","timestamp":1769677162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01236-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01236-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"YK conceived the content of this article and wrote the original manuscript. BO, HK, and HT contributed substantially to the revision of the manuscript. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}